Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
Sorafenib-induced Posterior Reversible Encephalopathy Syndrome in a Child With FLT3-ITD-positive Acute Myeloid Leukemia
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)(aEuro)
Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint
Sorafenib联合吡喹酮对日本血吸虫病小鼠肝纤维化病理学的作用
Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation
Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis
Sorafenib for the management of advanced renal cell carcinoma
Sorafenib in renal cell carcinoma
Sorafenib in the management of metastatic renal cell carcinoma
Sorafenib tosylate in advanced kidney cancer: past, present and future
Sorafenib Therapy for Hepatocellular Carcinoma in an HIV-HCV Coinfected Patient: A Case Report
Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression
Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy
Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis
Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor alpha
Sorafenib Inhibits STAT3 Activation to Enhance TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells
Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways
Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma
Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation
Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA
Sorafenib Treatment for Recurrent Hepatocellular Carcinoma After Liver Transplantation
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled
Sorafenib A Review of its Use in Advanced Hepatocellular Carcinoma
Sorafenib for the Treatment of HCC - The Beginning of a New Era in the Treatment of HCC
Sorafenib Inhibits the Hepatocyte Growth Factor-Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma
Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development
Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression
Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion
Sorafenib is active on lung metastases from synovial sarcoma
Sorafenib and radiotherapy association for hepatocellular carcinoma
Sorafenib Enhances the Antitumor Effects of Chemoradiation Treatment by Downregulating ERCC-1 and XRCC-1 DNA Repair Proteins
Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1
Sorafenib Use in Hepatocellular Carcinoma: More Questions Than Answers
Sorafenib and Vorinostat Kill Colon Cancer Cells by CD95-Dependent and -Independent Mechanisms
Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma
Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?
Sorafenib Enhances Pemetrexed Cytotoxicity through an Autophagy-Dependent Mechanism in Cancer Cells
Sorafenib in melanoma
Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model
Sorafenib and entecavir: The dioscuri of treatment for advanced hepatocellular carcinoma?
Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer
Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma
Sorafenib Ameliorates Renal Fibrosis through Inhibition of TGF-beta-Induced Epithelial-Mesenchymal Transition
Sorafenib in Advanced Hepatocellular Carcinoma
Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9
Sorafenib in metastatic thyroid cancer
Sorafenib in Metastatic Thyroid Cancer: A Systematic Review
Sorafenib for the treatment of thyroid cancer: an updated review
Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions
Sorafenib for advanced-stage hepatocellular carcinoma
Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study
Sorafenib and Everolimus in Advanced Clear Cell Renal Carcinoma: A Phase I/II Trial of the SCRI Oncology Research Consortium
Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia
Sorafenib Induced Thyroiditis in Two Patients with Hepatocellular Carcinoma
Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan
Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function REPLY
Sorafenib Inhibits TPA-Induced MMP-9 and VEGF Expression via Suppression of ERK/NF-kappa B Pathway in Hepatocellular Carcinoma Cells
Sorafenib Use in the Transplant Setting
Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
Sorafenib-Induced Tuberculosis Reactivation
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study
Sorafenib for Treatment of Hepatocellular Carcinoma: A Systematic Review
Sorafenib in Advanced Hepatocellular Carcinoma Hypertension as a Potential Surrogate Marker for Efficacy
Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation
Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group
Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production In Vitro and In Vivo
Sorafenib-induced annular pustular psoriasis (Milian-Katchoura type)
Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas
Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
Sorafenib Therapy in Patients with Advanced Hepatocellular Carcinoma in Advanced Liver Cirrhosis
Sorafenib (Nexavar (R), BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema
Sorafenib-associated hand-foot syndrome in Japanese patients
Sorafenib in non-small cell lung cancer
Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study
Sorafenib Triggers Antiproliferative and Pro-Apoptotic Signals in Human Esophageal Adenocarcinoma Cells
Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma
Sorafenib may prove a potential treatment for multiple myeloma patients
Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells
Sorafenib (Nexavar) for Thyroid Cancer
Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study
Sorafenib for HCC: A Pragmatic Perspective THE KIM ARTICLE REVIEWED
Sorafenib
Sorafenib: a clinical and pharmacologic review
Sorafenib-Induced Destructive Thyroiditis
Sorafenib after RFA in HCC Patients: a Pilot Study
Sorafenib in Elderly Patients with Advanced Hepatocellular Carcinoma: A Case Series
Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: Stable radiographic disease with decreased AFP